← All trials
NCT00760149
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2010
- Primary completion
- Sep 1, 2013
- Completion date
- Sep 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 150
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Radboud UniversityLead sponsor
- Radboud UniversityOverall official - principal investigator
- Kilimanjaro Christian Medical College, TanzaniaOverall official - principal investigator
- SanofiCollaborator
- European and Developing Countries Clinical Trials Partnership (EDCTP)Collaborator
- Kibong'oto National Tuberculosis Hospital, Sanya Juu, TanzaniaCollaborator
- Kilimanjaro Christian Medical College, TanzaniaCollaborator
- Radboud UniversityCollaborator
- National Institute for Public Health and the Environment, RIVM, HollandCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.